Press Releases

ThermoGenesis Announces Corning’s Commercial Launch of the X-SERIES® Cell Processing Products Developed by ThermoGenesis

Innovative Density Gradient Media-Free & Buoyancy-Activated Cell Sorting (BACS) Technologies Improve Manufacturing Efficiency and Yield of Cell & Gene-Therapy Products   RANCHO CORDOVA, Calif., June 23, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that, pursuant to its existing, … Continued

ThermoGenesis to Join Russell Microcap® Index

RANCHO CORDOVA, Calif., June 16, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market … Continued

ThermoGenesis Announces Filing of Patent Applications for Device that Improves the Accuracy of Lateral Flow Immunoassays (LFIA) in the Detection of COVID-19 Antibodies

RANCHO CORDOVA, Calif., June 11, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company has filed patent applications for a point-of-care device which improves the speed and accuracy of lateral flow immunoassays (LFIA) to detect COVID-19 IgM … Continued

ThermoGenesis Announces That Results of ImmuneCyte’s Licensed Neutralizing Antibody Therapeutics for COVID-19 Were Published in bioRxiv

RANCHO CORDOVA, Calif., June 8, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, the research partner of ThermoGenesis’ joint venture, ImmuneCyte, Inc., published the … Continued

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2020 and Provide a Corporate Strategic Update

Conference Call to be Held on May 14, 2020 RANCHO CORDOVA, Calif., May 7, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2020 … Continued

ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19, Featured on FOX40 and Other Local News Outlets

RANCHO CORDOVA, Calif., April 24, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that it was featured on multiple new outlets, including a Fox40 news segment titled, “Rancho Cordova Company Says It’s Working on Potential Treatment for Coronavirus,” regarding … Continued

ThermoGenesis Receives Acknowledgement Letter from FDA Allowing Its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit for Distribution

RANCHO CORDOVA, Calif., April 16, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that on Wednesday April 15th, following submission of notification to the U.S. Food and Drug Administration (FDA), the Company has received the necessary acknowledgement letter which … Continued

ThermoGenesis Announces Its ImmuneCyte Joint Venture Acquires Key Technologies to Develop Fully Human Polyclonal and Monoclonal Antibody Therapeutics for COVID-19

RANCHO CORDOVA, Calif., April 13, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that its joint venture, ImmuneCyte Life Sciences, Inc., has completed the acquisition of worldwide intellectual property for developing fully human antibody therapeutics for COVID-19. The acquired … Continued

How may we help?